OncoMatch/Clinical Trials/NCT05055648
PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy
Is NCT05055648 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies non-drug interventions for esophageal cancer.
The PROTECT trial will test the hypothesis that proton (PT) -enabled radiation dose reductions to sensitive, normal tissues will result in lower rates of treatment-related pulmonary complications in esophageal cancer compared to standard photon therapy (XT).
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage CT1-4A, CN+, CM0 (TNM (8th edition))
Tumor stage according to TNM (8th edition): cT1-4a and/or cN+, cM0
Performance status
WHO 0–2
Prior therapy
Cannot have received: thoracic radiation therapy
Prior thoracic XT or PT
Cannot have received: chemotherapy
Prior ... chemotherapy ... in the esophageal/gastric region
Cannot have received: surgical resection in the esophageal/gastric region
Exception: previous EMR or ESD is allowed
Prior ... surgical resection in the esophageal/gastric region (previous EMR or ESD is allowed)
Lab requirements
Blood counts
hemoglobin > 90 g/L, absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L, platelets ≥ 75 x 10^9/L
Kidney function
creatinine ≤ 1.5 x ULN, GFR > 30 ml/min
Liver function
bilirubin ≤ 1.5 x upper limit of normal (ULN), ALAT ≤ 3 x ULN
Adequate laboratory findings: hematological: hemoglobin > 90 g/L, absolute neutrophil count (ANC) ≥ 1,5 x 109/L, platelets ≥ 75 x 109/L hepatic: bilirubin ≤ 1.5 x upper limit of normal (ULN), ALAT ≤ 3 x ULN renal: creatinine ≤ 1.5 x ULN, GFR (may be calculated) > 30 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05055648 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior thoracic radiation therapy, chemotherapy, surgical resection in the esophageal/gastric region disqualifies patients from enrollment.
What disease stage is eligible?
Stage CT1-4A or CN+ or CM0 is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages